Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
New Downtrend | Bearish | 5.40% | |
Wide Bands | Range Expansion | 5.40% | |
Gapped Up | Strength | 5.40% | |
Oversold Stochastic | Weakness | 5.40% | |
Outside Day | Range Expansion | 3.54% | |
Wide Bands | Range Expansion | 3.54% | |
Oversold Stochastic | Weakness | 3.54% | |
180 Bearish Setup | Bearish Swing Setup | 5.88% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 2 days ago |
10 DMA Resistance | 2 days ago |
Rose Above Previous Day's High | 2 days ago |
Up 1 ATR | 2 days ago |
Gap Up Partially Closed | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 31.46 |
52 Week Low | 9.56 |
Average Volume | 813,524 |
200-Day Moving Average | 16.78 |
50-Day Moving Average | 13.81 |
20-Day Moving Average | 12.61 |
10-Day Moving Average | 11.60 |
Average True Range | 0.93 |
RSI (14) | 41.52 |
ADX | 25.57 |
+DI | 12.54 |
-DI | 23.77 |
Chandelier Exit (Long, 3 ATRs) | 13.43 |
Chandelier Exit (Short, 3 ATRs) | 13.17 |
Upper Bollinger Bands | 15.25 |
Lower Bollinger Band | 9.98 |
Percent B (%b) | 0.33 |
BandWidth | 41.79 |
MACD Line | -0.79 |
MACD Signal Line | -0.69 |
MACD Histogram | -0.1017 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.70 | ||||
Resistance 3 (R3) | 12.72 | 12.42 | 12.54 | ||
Resistance 2 (R2) | 12.42 | 12.16 | 12.41 | 12.48 | |
Resistance 1 (R1) | 12.06 | 12.01 | 12.24 | 12.04 | 12.42 |
Pivot Point | 11.76 | 11.76 | 11.85 | 11.75 | 11.76 |
Support 1 (S1) | 11.40 | 11.50 | 11.58 | 11.38 | 11.00 |
Support 2 (S2) | 11.10 | 11.35 | 11.09 | 10.94 | |
Support 3 (S3) | 10.74 | 11.10 | 10.89 | ||
Support 4 (S4) | 10.72 |